Stock Price & Analysis

Based on the technical analysis and recent analyst reports, here's a concise assessment of STE stock:

The stock is showing mixed signals with RSI at 53.01 indicating neutral momentum. Recent price action has formed a consolidation pattern between $215-$230, with current trading at $229.03.

According to recent analyst coverage, Needham maintains a Hold rating while the Street consensus suggests a Moderate Buy with a $253.33 price target, indicating a potential upside of about 10.6%. However, insider sentiment is notably negative, with 55 insiders selling shares recently.

Technical support levels are found at $215.93 (Fibonacci S1) and resistance at $225.98 (Fibonacci R1). The stock is currently trading above its 20-day SMA ($219.88) but below its 200-day SMA ($223.30), suggesting a neutral-to-slightly-bullish short-term trend.

Given the mixed signals and current valuation, holding STE stock appears to be the most prudent action at this time. The stock shows neither strong buy nor sell signals in the immediate term.

Based on the available data and analysis, here is the price prediction for STE (Steris) stock in 2025:

Technical Analysis

The technical indicators show:

• RSI(14) at 53.01 indicates neutral momentum
• MACD is slightly bullish with MACD line at 2.27 above signal line
• Stock is trading between 20-day SMA ($219.88) and 200-day SMA ($223.30)
• Current price around $219.34 is near the middle of Bollinger Bands (BBP: 0.47)

Fundamental Drivers

• Recent insider selling activity shows negative sentiment, with 55 insiders selling shares
• Analysts maintain moderate buy consensus with average price target of $253.33
• JMP Securities maintains Buy rating with $265 target, suggesting ~20% upside potential

Price Target Scenarios for 2025:

1. Bullish Case ($265):

• Successful execution of growth initiatives
• Continued healthcare sector strength
• Probability: 40%

2. Base Case ($235):

• Moderate growth in line with sector
• Some margin pressure from costs
• Probability: 45%

3. Bearish Case ($210):

• Increased competition
• Margin compression
• Probability: 15%

Most likely scenario: Base case target of $235, representing ~7% upside from current levels, driven by:

• Stable healthcare sector demand
• Strong market position
• Balanced risk/reward profile

The S1 support level for STE Stock is $216.34 ,The R1 resistant level for STE Stock is $225.25.

As of the end of day on 2025-02-21, the price of STE Stock was $220.56.

The target price for STE Stock according to analyst rating is 265.00, with the highest price target at 265.00 and the lowest at 265.00. Analysts have a Moderate Buy rating on STE Stock overall.

The market cap of STE is $21.7B.

Based on the provided data and recent analyst reports, I'll analyze whether STE is overvalued through multiple perspectives.

Technical Analysis The stock is currently trading at $219.34, below its 200-day moving average of $223.30, indicating some bearish pressure. RSI-14 at 53.01 suggests neutral momentum.

Valuation Analysis

• Forward P/E ratio has improved from 179.16x (FY2023) to current levels
• EV/EBITDA decreased from 21.34x to 16.25x, showing better operational efficiency
• Price-to-Sales ratio declined from 5.18x to 3.87x, indicating more reasonable valuation
• Price-to-Book ratio reduced from 3.70x to 3.10x

Recent Performance & Growth

• Revenue grew 7.33% YoY
• Net margin of 11.29% shows solid profitability
• ROE at 2.32% indicates room for improvement in capital efficiency
• Debt-to-equity ratio of 0.36 demonstrates conservative financial leverage

Analyst Consensus Recent analyst coverage shows strong positive sentiment:

• Average price target: $258.75
• High target: $265.00
• Low target: $240.00
• Current consensus rating: Market Outperform

Conclusion Based on improving valuation metrics, solid revenue growth, and strong analyst support targeting ~18% upside, STE appears reasonably valued at current levels rather than overvalued.

STERIS plc is a provider of products and services that support patient care with an emphasis on infection prevention. The Company’s segments include Healthcare, Applied Sterilization Technologies, Life Sciences and Dental. The Healthcare segment is focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. Its Applied Sterilization Technologies (AST) segment is a third-party service provider for contract sterilization, as well as testing services needed to validate sterility services for medical device and pharmaceutical manufacturers. Its Life Sciences segment provides a comprehensive offering of products and services that support pharmaceutical manufacturing, primarily for vaccine and other biopharma customers focused on aseptic manufacturing. Its Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems.

Based on the available data and analysis, here is the price prediction for STE (Steris) stock by 2030:

STE stock is projected to reach $285-295 by 2030, representing a 30-35% upside from current levels, driven by:

Growth Drivers:

• Continued expansion in healthcare sterilization and infection prevention markets
• Strong recurring revenue model from consumables and service
• Strategic investments in new technologies and facility expansions
• Growing demand from aging population and increased focus on infection control

Current Market Position:

• Trading at $219.34 as of Feb 14, 2025
• RSI at 53.01 indicates neutral momentum
• Support levels around $215.93 and resistance at $225.98
• Consensus analyst rating is Moderate Buy with $253.33 price target

Key Considerations:

• Healthcare sector expected to see sustained growth through 2030
• Company's strong market position in infection prevention
• Consistent investment in R&D and new technologies
• Potential headwinds from increased competition and pricing pressure

The projection assumes:

• 8-10% annual revenue growth
• Stable operating margins
• Continued market leadership in core segments
• No major disruptions to healthcare spending

STE has a total of 17000 employees.